These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

610 related items for PubMed ID: 19528811

  • 1. Evolving mechanisms of action of beta blockers: focus on nebivolol.
    Mason RP, Giles TD, Sowers JR.
    J Cardiovasc Pharmacol; 2009 Aug; 54(2):123-8. PubMed ID: 19528811
    [Abstract] [Full Text] [Related]

  • 2. [Role of the L-arginine/nitric oxide system in the action of nebivolol].
    Brodde OE, Philipp T.
    Dtsch Med Wochenschr; 2006 Nov 10; 131(45):2545-50. PubMed ID: 17091442
    [Abstract] [Full Text] [Related]

  • 3. Nitric oxide mechanisms of nebivolol.
    Maffei A, Lembo G.
    Ther Adv Cardiovasc Dis; 2009 Aug 10; 3(4):317-27. PubMed ID: 19443516
    [Abstract] [Full Text] [Related]

  • 4. Nebivolol: a third-generation beta-adrenergic blocker.
    Veverka A, Nuzum DS, Jolly JL.
    Ann Pharmacother; 2006 Aug 10; 40(7-8):1353-60. PubMed ID: 16822893
    [Abstract] [Full Text] [Related]

  • 5. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide.
    Gupta S, Wright HM.
    Cardiovasc Ther; 2008 Aug 10; 26(3):189-202. PubMed ID: 18786089
    [Abstract] [Full Text] [Related]

  • 6. Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol.
    Ignarro LJ.
    Cardiovasc Ther; 2008 Aug 10; 26(2):115-34. PubMed ID: 18485134
    [Abstract] [Full Text] [Related]

  • 7. The role of the new beta-blockers in treating cardiovascular disease.
    Weber MA.
    Am J Hypertens; 2005 Dec 10; 18(12 Pt 2):169S-176S. PubMed ID: 16373195
    [Abstract] [Full Text] [Related]

  • 8. The role of nitric oxide in improving endothelial function and cardiovascular health: focus on nebivolol.
    Bakris GL, Basile JN, Giles TD, Taylor AA.
    Am J Med; 2010 Jul 10; 123(7 Suppl 1):S2-8. PubMed ID: 20609695
    [Abstract] [Full Text] [Related]

  • 9. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart.
    Rozec B, Erfanian M, Laurent K, Trochu JN, Gauthier C.
    J Am Coll Cardiol; 2009 Apr 28; 53(17):1532-8. PubMed ID: 19389564
    [Abstract] [Full Text] [Related]

  • 10. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW.
    Clin Ther; 2009 Mar 28; 31(3):447-62. PubMed ID: 19393838
    [Abstract] [Full Text] [Related]

  • 11. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker.
    Ignarro LJ.
    Blood Press Suppl; 2004 Oct 28; 1():2-16. PubMed ID: 15587107
    [Abstract] [Full Text] [Related]

  • 12. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol.
    Dessy C, Saliez J, Ghisdal P, Daneau G, Lobysheva II, Frérart F, Belge C, Jnaoui K, Noirhomme P, Feron O, Balligand JL.
    Circulation; 2005 Aug 23; 112(8):1198-205. PubMed ID: 16116070
    [Abstract] [Full Text] [Related]

  • 13. Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blocker.
    Prisant LM.
    J Clin Pharmacol; 2008 Feb 23; 48(2):225-39. PubMed ID: 18083889
    [Abstract] [Full Text] [Related]

  • 14. Beta-blockers in the management of hypertension: focus on nebivolol.
    Wojciechowski D, Papademetriou V.
    Expert Rev Cardiovasc Ther; 2008 Apr 23; 6(4):471-9. PubMed ID: 18402537
    [Abstract] [Full Text] [Related]

  • 15. Nebivolol: the somewhat-different beta-adrenergic receptor blocker.
    Münzel T, Gori T.
    J Am Coll Cardiol; 2009 Oct 13; 54(16):1491-9. PubMed ID: 19815121
    [Abstract] [Full Text] [Related]

  • 16. No-dependent vasodilation induced by nebivolol in coronary circulation is not mediated by beta-adrenoceptors or by 5 HT1A-receptors.
    Chlopicki S, Kozlovski VI, Gryglewski RJ.
    J Physiol Pharmacol; 2002 Dec 13; 53(4 Pt 1):615-24. PubMed ID: 12512696
    [Abstract] [Full Text] [Related]

  • 17. Nebivolol: new therapy update.
    Sule SS, Frishman W.
    Cardiol Rev; 2006 Dec 13; 14(5):259-64. PubMed ID: 16924166
    [Abstract] [Full Text] [Related]

  • 18. Nebivolol: an endothelium-friendly selective β1-adrenoceptor blocker.
    Gao Y, Vanhoutte PM.
    J Cardiovasc Pharmacol; 2012 Jan 13; 59(1):16-21. PubMed ID: 21283024
    [Abstract] [Full Text] [Related]

  • 19. The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various beta-adrenergic blockers.
    Pauwels PJ, Gommeren W, Van Lommen G, Janssen PA, Leysen JE.
    Mol Pharmacol; 1988 Dec 13; 34(6):843-51. PubMed ID: 2462161
    [Abstract] [Full Text] [Related]

  • 20. Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection.
    Mahmud A, Feely J.
    Am J Hypertens; 2008 Jun 13; 21(6):663-7. PubMed ID: 18437130
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.